Branch² Intelligence

Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II

US · 2026-08-14

Key takeaway

FDA proposes reclassification of Blue Light Cystoscopy Systems from Class III to Class II.

  1. Step 1 · The triggerFDA proposes reclassification of Blue Light Cystoscopy Systems to Class II.
  2. Step 2 · Knock-onReduced regulatory burdens lower compliance costs for manufacturers.
  3. Step 3 · Reaches youIncreased market access and sales potential for Photocure ASA.

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: PR Newswire

See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for SMEs

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.